compared. Finally, the BCF provides an assessment of sensitivity; the larger the BCF, the less the sensitivity of the assay. Also, one can use the BCF to correct absorbance to absolute absorbance, and determine molar absorptivities, e.g., when using the Benesi-Hildebrand equation. In summary, three practical applications of the Bcf are wavelength applications, sensitivity assessment and correction of absorbance. Resultsof an immunoenzymetncassay (TANDEM#{174}-E cKMB) for creatine kinase (CK; EC 2.7.3.2) MB isoenzyme, in which subunit-specificmonoclonalantibodiesare used, were compared with those by an immunochemicalmethod (Isomune-CK'") and electrophoresis(Coming agarose gel). The study involved200 patients; >500 samples were analyzed by all Although it is measured electrophoretically by most clinical laboratories (2), immunological methods have recently become available. However, some of these methods are not specific for CK-MB; for example, the radioimmunoassay of the B subunit (3) and the immunoinhibition assay of the M subunit (4) measure both CK-MB and CK-BB. Moreover, the analytical and clinical performance of these methods is not always satisfactory (5). Alternatively, the specific inimunoradiometric assay can be used to clearly differentiate acute myocardial infarct (AM!) patients from non-AM! patients in a coronary-care unit (6).
CK"). Here we report an evaluation of a new immunometi-ic assay, TANDEM#{174}-E ca
(Hybritech), which involves an enzyme label and two monoclonal antibodies, one directed against the B subunit and the other against the M subunit. We compared results for CK-MB in serum from 200 patients, as determined by the Roche inimunocheinical method with a centrifugal analyzer, Corning agarose gel electrophoresis, and the Hybritech immunoenzymetric assay.
Materials and Methods

Methods
TANDEM-E
ImmunoEnzymetric CKMB (Hybritech Inc., San Diego, CA 92121) is a solid-phase, two-site immunoassay in which two monoclonal antibodies are used to measure the intact CK-MB molecule. The antibody-antigen binding reaction involves a 2-h incubation followed by a 30-mm reaction with alkaline phosphatase (EC 3.1.3.1). The absorbance is measured at 405 nm, in the Hybritech Photon photometer. A linear calibration curve is established by using two calibrators (zero and about 60 t.g/L). All patients' samples, calibrators, and controls were analyzed in duplicate and the results averaged according to the manufacturer's recommendation. Any specimens having a result greater than 100 g/L were diluted fivefold with the Zero Diluent and re-assayed. Two quality-control samples were used in this procedure: Hybritech CKMB Low and High Control.
Isomune-CK (Roche Diagnostics, Nutley, NJ 07110) is an immunochemical method for quantification of CK-MB isoenzyme. The reagents are anti-CK-M serum (goat) and polymer-bound donkey anti-goat inununoglobulin.
To two tubes, each containing 200 zL of patient's serum, is added the goat anti-M serum (250 pL to tube 1 and 50 pL to tube 2). Tube 1 is incubated for 20 mm to completely inhibit all M-subunit activity. Tube 2 is incubated for 5 mm with anti-M serum and an additional 5 mm with anti-goat gammaglobulin bound to a polymer. The tube and contents are then centrifuged to remove insoluble complexes of M-containing isoenzymes. The residual CK activity in tube 1 and the activity of the supernate of tube 2 is measured in a centrifugal analyzer (Cobas-Bio; Roche Analytical Instruments, Montclair, NJ 07042) with the reagent system described for the measurement of total CK. The activity in Tube 1 represents that of CK-B subunits from both CK-MB and CK-BB isoenzymes, plus any activity from atypical CKs and adenylate kinase. That in tube 2 represents the activity of the CK-BB isoenzyme, atypical CKs, and adenylate kinase. The difference between measurements for tube 1 and tube 2 represents the activity of the B-subunit of CK-MB. Multiplied by 2, this number represents the activity of the entire CK-MB isoenzyme. Samples with a total CK activity >1000 U/L or whose activity in tube 2 exceeds that in tube 1 are diluted fivefold with isotonic saline and re-assayed. Three quality control samples were included with each batch of specimens: Roche Cardiotrol-CK and Hybritech CKMB Low and High Control.
Electrophoresis was performed on Corning ACI agarose ifim (Corning Medical and Scientific, Palo Alto, CA 94306) and Corning AC! "r&oi'so" buffer was used. Any samples with a total CK activity >1000 U/L were diluted with saline before electrophoresis.
After electrophoresis the gel was overlaid with Corning "Cardiotrak-CK" substrate and incubated at 37 #{176}C for 20 mm. After sufficient drying, the ifim was examined under an ultraviolet lamp, with a qualitycontrol sample (I.D. Zone Liquid CK Isoenzyme Control;
Beckman
Instruments, Brea, CA 92621) as reference, and the presence or absence of MB and BB bands was noted. Any specimens positive for MB or BB were subsequently scanned by fluorescence densitometry with a Beckman CDS 100 densitometer.
Total CK activity was measured by using "BMD Fastchem CK-NAC (activated)" (Boehringer Mannheim Diagnostics, Indianapolis, IN 46250) and the Cobas-Bio analyzer. 
Patients
We studied samples from 200 consecutive patients, submitted for electrophoretic determination of CK-MB. On the average, there were three samples per patient; only samples with sufficient volume for analysis by all three methods were included in this report. All samples were stored frozen until analysis.
The patients, admitted for various disorders, were classified into four diagnostic groups:
Group 1 patients were diagnosed as having acute myocardial infarction (AM!). Group 4 patients were those who did not fit into the preceding three groups, including patients with trauma of chest or head, seizures, polymyositis, cardiac surgery, questionable AM!, and patients for whom samples had been collected at inappropriate times for AM! patients.
Our method correlation study includes all results for these patients. The predictive value calculation is based on group 1 as the patients with AM! and on groups 2 and 3 as patients without AM!. An ideal CK-MB test should have an above-normal result for the AM! patient and a "normal" result for the non-AM! patient.
Results
Precision.
Interassay precision, as calculated from quality-control samples analyzed during six months, is shown in Table 2 . The detection limits for the Roche and Hybritech methods, calculated as the mean +2 SD for 20 replicates of the zero calibrator from the Hybritech kit, were 2.0 U/L and 3.0 g/L, respectively. The detection limit of Corning electrophoresis reported in the package insert was 2.0 U/L. The reference interval for the "normal" patients was determined from data on 100 patients' samples submitted for continuous-flow analysis with the Technicon sc analyzer. For all, the chemical and enzymic values were within our "normal" range. Both parametric and nonparametric statistics gave similar reference intervals for normal: 0-4.0 1ug/L for the TANDEM-E cira and 0-4 U/L for the Roche Isomune-CK. The reference intervals for the "non-AM!" patients by each of the three methods, determined from data on 86 patients (groups 2 and 3) diagnosed as being without AM!, were 0-9 gfL (TANDEM-E cxa), 0-14 UIL (!somune-CK), and 0-7 U/L (0-4% of total CK) by electrophoresis. These intervals were chosen to minimize the number of falsely positive and falsely negative CK-MB results for each method.
Linearity.
We evaluated assay linearity by diluting samples with increased CK-MB with the zero calibrator from the Hybritech kit. Both TANDEM-E CKMB and Isomune-CK exhibit good linearity except at very low CK-MB activities. This deviation is probably attributable to the imprecision of both methods at "normal" CK-MB concentration.
The TANDSM-E KMB results correlate well with electrophoretic results, but the data show considerable scatter. Nevertheless, the ratio of CK-MB activity (U/L) by electrophoresis to the quantity of CK-MB (jzgfL) as measured by the TANDEM-E cxa assay is almost one to one. Results by these two methods still correlate quite well for samples requiring dilution (Table 3) . Results by Isomune-CK also correlate well with those by electrophoresis, although several samples had measurable activity by Isomune-CK but An Table 4 summarizes our methods comparisons based on the agreement of their peak CK-MB results defined by their reference intervals for AM!. Ninety-six percent of the results agree between TANDEM-E cius and electrophoresis, with five discrepancies, and 90% agreed between Isomune-CK and electrophoresis, with 13 discrepancies.
Of these 13 discrepancies, 10 values were negative by Isomune-CK but positive by electrophoresis.
The predictive values (8) were calculated by using the activity or quantity of CK-MB as well as CK-MB as a percentage of total CK activity ( Table 5) . For TANDEM CKMB, we first derived a relative index by dividing the quantity of CK-MB measured (g/L) by the total CK activity (U/L) and expressed this as "percentage" of total CK.
By the previously listed criteria, 38 patients were diagnosed as having AM!, with only one false-negative assessment from CK-MB by electrophoresis (in U/L), a patient with a CK-MB of 4 U/L. However, electrophoresis resulted in seven false negatives as assessed by the percentage of total CK. The Roche Isomune-CK gave seven false negatives, ranging from 8 to 14 UIL. Two false negatives were reported for TANDEM-E cx: 6 and 7 gfL. Expressing the results as a "percentage" of total CK produces more false negatives.
The greatest sensitivity (97%) is achieved by electrophoresis in U/L, followed closely (95%) by TANDEM-E CKMB in fLg/L. The best specificity (94%) is from the electrophoresis results for percent of total activity. The predictive value of a positive CK-MB result is relatively low. The highest predictive value of a positive result is only 86% by electrophoresis and the lowest is 72% by Isomune-CK (both for % of total CK). The predictive value of a negative CK-MB for all three methods ranges from 88 to 99%. The best overall diagnostic efficiencies (>90%) are obtained by electrophoresis in U/L or %, and TANDEM-E CKMB in Ag/L.
Discussion
Agarose gel electrophoresis is used by most clinical laboratories for CK-MB determination. Our goal was to determine if either the immunochemical assay or the immunoenzymetric assay with monoclonal antibodies could be used to replace the traditional electrophoretic technique. The precision of both immunologic assays is at least as good or better than that of electrophoresis ( Table 2 ). The linearity of the dilution curve for samples with CK-MB within the dynamic range of the assay is quite good for both assays. However, for Isomune CK, diluting samples with total CK activity >6000 U/L appears to cause problems. For such samples, undiluted, the activity in the second tube always exceeds that in the first tube, which results in apparently negative CK-MB activity. Thus, the amount of antibody in the assay appears We determined two different reference intervals, one for the "normal" patients and the other for "non-AM!" patients. We emphasize that the one-to-one correspondence of CK-MB by TANDEM and by electrophoresis in the correlation study is probably a coincidence. The CK-MB by electrophoresis is calculated from the percentage of each isoenzyme, multiplied by the total CK activity. Therefore, the result depends on the method for determining total CK and the temperature of enzyme analysis. The method we used for total CK, with the N-acetylcysteine-activated reagent, is performed at 37#{176}C. Another laboratory, using a different reagent system or a different temperature of analysis (e.g., 30#{176}C), will obtain different numerical results for CK-MB by electrophoresis.
Furthermore, the TANDEM immunoassay measures the enzyme mass, presumably both catalytically active and inactive enzymes. For example, the qualitycontrol samples in the precision study (Table 2) showed very different results for activity vs quantity, as determined by Isomune and TANDEM CE-MB. Presumably, there is more inactive CK in the quality-control sample than in the fresh human serum.
Agreement between methods based on the peak CK-MB values for each patient is good, given that 90% or more of the patients were similarly classified as either positive or negative for CK-MB (Table 4) . Of the two patients with above-normal CK-MB by TANDEM CKMB but not by electrophoresis, one has congestive heart failure without ECG changes; the other patient, admitted to the hospital for replacement of the total hip joint, presented with chest pain but no ECG changes. Of the three patients with abovenormal CK-MB by electrophoresis but not by TANDEM CK-MB, one was diagnosed as AM! with unstable angina, one was admitted for the removal of kidney tumor and developed cardiopulmonary arrest complicated with anoxic encephalopathy, and the other patient was found to be unconscious and presented with chronic dementia and abnormal ECG changes. The three patients with above-normal CK-MB by !somune but not by electrophoresis were a patient with angina, one with gastrointestinal bleeding, and a chronic alcoholic patient admitted with seizure (total CK >10 000 UIL). The 10 patients with above-normal CK-MB by electrophoresis but not by !somune consisted of six patients with AM!, one a patient with cardiac catherization, and the three patients above, whose CK-MB was abovenormal by electrophoresis but not by TANDEM CK-MB.
Readers should be aware of the limitation of comparing predictive values by electrophoresis with those by the immunoassays, because the electrophoretic results for CK-MB were used as one of the criteria for establishing AM!. Since this is the first published study of the TANDEM-E CKMB, we can only compare our findings with other studies of immunoassays. We report acceptable clinical performance of the TANDEM-E ci assay with a sensitivity of 95%, a specificity of 91%, a positive predictive value of 82%, a negative predictive value of 98%, and an overall efficiency of 92%. De Puey et al. (10) studied an immunoradiometric assay for CK-MB in which two polyclonal antibodies formed a "sandwich" assay; for a selected group of 144 patients undergoing aortocoronary bypass surgery, the sensitivity was 88%, specificity 99%, positive predictive value 95%, and accuracy 97% for using CK-MB as a postoperative screening test to confirm the presence of perioperative myocardial infarction. In another study, using a different imniunoradiometric assay for CK-MB, Kwong et al. (6) reported good agreement between the immunoassay and electrophoresis for 19 patients with AM! and 31 patients without AM! in the coronary care unit; diagnostic sensitivity and specificity were almost 100% for both methods.
Unlike these previous reports, our study includes a relatively large percentage of non-AM! patients with other cardiac diseases. These patients had significant amounts of CK-MB present, and some of them were classified as false positives in the non-AM! group. Recently, Hybritech
Inc. has recommended using both CK-MB >9 pg/L and CK-MB >3.9% of total CK as decision criteria for AM! diagnosis. By those criteria, the overall efficiency of our study remains the same as we reported. However, we find that the relative index of CK-MB as a "percentage" of total CK is also useful when the total CK is very high.
The sensitivity of the Isomune-CK for AM! was 82%, with 91% specificity and 88% efficiency-less than the 95% sensitivity and 95% specificity reported by Mi et al. (11) , again, probably because of differences in patient selection. The manufacturer recommended using an upper limit of normal for CK-MB of 10 U/L. When we used this limit to calculate predictive values, efficiency was lower at 86%, and specificity was 84%; however, sensitivity was higher, 92%. The Isomune-CK had many more false positives for the non-AM! patients. Examination of all the CK-MB data showed numerous discrepancies. Of the 68 samples with nondetectable CK-MB by electrophoresis, 48 samples had detectable CK-MB (up to 18 UIL) by !somune-CK, similar to the experience of Bruns et al. (9) . Although one may argue that Isomune-CK may be more sensitive than electrophoresis in detecting the presence of CK-MB (which seems to be the case for samples with very low CK-MB), the large number of values in the 10-18 U/L range suggests that more numerous false positives by the Isomune-CK assay are related to the use of 10 UfL as the upper limit of normal. Therefore, we raised the limit to 14 UIL, for the best overall efficiency. To evaluate the CK-MB result for diagnosis of AMI, we recommend using the reference interval of 0 to 14 U/L, as well as MB as a percentage of total CK, for samples with very high total CK activity.
We reported a lower percentage efficiency not only for the two immunoassays but also for the Corning electrophoresis method, as compared with other reports (12). Most studies evaluated patients in the coronary care unit, among whom the prevalence of AM! is greater. We evaluated not only such patients but also other patients suspected of AM! or who were being evaluated for possible CK-MB in serum. We found increased CK-MB results in the following conditions: congestive heart failure, angina, cardiac catheterization, aortic stenosis complicated with pulmonary edema, severe arrhythmia, cardiogenic shock, septal ischemia, cardiopulmonary arrest complicated with anoxic encephalopathy, alcohol abuse, acute gastrointestinal bleeding, dementia, traumatic epilepsy, seizures, chest trauma, polymyositis, trauma, cardiopulmonary resuscitation, and cardiac surgery. This is in agreement with a recent review article by Lott (13), who reported increased serum CK-MB without AM! in a variety of these clinical conditions.
We conclude that all three methods are capable of accurately detecting CK-MB in serum and that results of all three methods show considerable agreement.
However, the methods differ in their analytical as well as clinical ability to confirm or rule out AM!.
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